In vivo data highlights the specific tissue and cellular targeting capabilities of ReNeuron’s stem cell derived exosome drug delivery platform, CustomEXTM

08 November 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that Dr Samantha Thomas will be presenting in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of ReNeuron’s CustomEX™ drug delivery platform, at Cell 2023 in London.

Read more…